These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 17094333

  • 1. Leflunomide in clinical practice.
    Pinto P, Dougados M.
    Acta Reumatol Port; 2006; 31(3):215-24. PubMed ID: 17094333
    [Abstract] [Full Text] [Related]

  • 2. Safety evaluation of leflunomide in rheumatoid arthritis.
    Keen HI, Conaghan PG, Tett SE.
    Expert Opin Drug Saf; 2013 Jul; 12(4):581-8. PubMed ID: 23668332
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action for leflunomide in rheumatoid arthritis.
    Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ.
    Clin Immunol; 1999 Dec; 93(3):198-208. PubMed ID: 10600330
    [Abstract] [Full Text] [Related]

  • 4. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis.
    Karanikolas G, Charalambopoulos D, Andrianakos A, Antoniades C, Katsilambros N.
    J Rheumatol; 2006 Mar; 33(3):486-9. PubMed ID: 16511917
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of action of leflunomide in rheumatoid arthritis.
    Fox RI.
    J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
    [Abstract] [Full Text] [Related]

  • 6. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.
    Perdriger A, Mariette X, Kuntz JL, Brocq O, Kara-Terki R, Loet XL, Cantagrel A, Pavy S, Deslandre CJ, Debiais F, Combe B, Club Rheumatismes et Inflammation.
    J Rheumatol; 2006 May; 33(5):865-9. PubMed ID: 16652418
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
    Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M.
    Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
    [Abstract] [Full Text] [Related]

  • 9. Leflunomide.
    Cannon GW, Kremer JM.
    Rheum Dis Clin North Am; 2004 May; 30(2):295-309, vi. PubMed ID: 15172042
    [Abstract] [Full Text] [Related]

  • 10. The broadening use of leflunomide in clinical practice.
    Kiely PD.
    Hosp Med; 2004 Dec; 65(12):735-9. PubMed ID: 15624449
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Leflunomide-associated pancytopenia with or without methotrexate.
    Chan J, Sanders DC, Du L, Pillans PI.
    Ann Pharmacother; 2004 Dec; 38(7-8):1206-11. PubMed ID: 15187208
    [Abstract] [Full Text] [Related]

  • 15. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified?
    Rajakulendran S, Gadsby K, Deighton C.
    Musculoskeletal Care; 2008 Dec; 6(4):233-45. PubMed ID: 18702106
    [Abstract] [Full Text] [Related]

  • 16. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
    O'Doherty C, Schnabl M, Spargo L, Cleland LG, James M, Proudman SM, Wiese MD.
    Pharmacogenomics; 2012 Sep; 13(12):1427-34. PubMed ID: 22966891
    [Abstract] [Full Text] [Related]

  • 17. Is leflunomide as safe and effective in the treatment of rheumatoid arthritis as other DMARDs?
    Schooff M, Wickersham J.
    Am Fam Physician; 2003 Sep 01; 68(5):849-50. PubMed ID: 13678131
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
    Breedveld FC, Dayer JM.
    Ann Rheum Dis; 2000 Nov 01; 59(11):841-9. PubMed ID: 11053058
    [Abstract] [Full Text] [Related]

  • 20. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients.
    Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, Salisbury D, Singh JA, Stern R, Zarabadi SA.
    Arthritis Rheum; 2003 Dec 15; 49(6):745-51. PubMed ID: 14673959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.